Literature DB >> 24818730

The role of inflammatory cells in angiogenesis in multiple myeloma.

Domenico Ribatti1, Angelo Vacca.   

Abstract

Both innate and adaptive immune cells are involved in the mechanisms of endothelial cell proliferation, migration and activation, via production and release of a large spectrum of pro-angiogenic mediators, thus creating the specific microenvironment that favors increased rate of tissue vascularization. In this article, we focus on the immune cell component of the angiogenic process occurring during multiple myeloma progression. We also provide information on some anti-angiogenic properties of immune cells that may be applied for a potential pharmacological use as anti-angiogenic agents in the disease treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24818730     DOI: 10.1007/978-3-0348-0837-8_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

2.  Prognostic Significance of Inflammatory Biomarkers in Patients with Breast Cancer Skeletal Metastases.

Authors:  Yuan Wang; Guilin Huang; Zhigang Li
Journal:  Cancer Manag Res       Date:  2020-11-09       Impact factor: 3.989

Review 3.  Diverse exocytic pathways for mast cell mediators.

Authors:  Hao Xu; Na-Ryum Bin; Shuzo Sugita
Journal:  Biochem Soc Trans       Date:  2018-02-22       Impact factor: 5.407

4.  Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-κB pathway.

Authors:  Yuanyuan Sun; Jing Pan; Ning Zhang; Wei Wei; Shanshan Yu; Limei Ai
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

5.  IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression.

Authors:  Yuanyuan Sun; Jing Pan; Shudan Mao; Jieping Jin
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.